Treatment efficacy of fecal microbiota-based live biotherapeutics (RBX2660) for the prevention of recurring Clostridioides difficile infection.

• C. difficile infections (CDI) are potentially deadly and serious infections. • Around 35% of CDI cases recur despite antibiotic treatment. • This meta-analysis pooled 580 participants across 6 trials. • Odds ratio of 1.82 (95% CI = 1.37–2.41) was reported favoring fecal microbiota use. • In-treatment group efficacy was 72% (95% CI = 68–76%). [ABSTRACT FROM AUTHOR]